Brief: NewLink Genetics Responds To Proposal From Evercel
16/12/2019 14:32
Dec 16 (Reuters) - NewLink Genetics Corp NLNK.O :
* NEWLINK GENETICS RESPONDS TO PROPOSAL FROM EVERCEL
* NEWLINK GENETICS - THOROUGHLY EVALUATED EVERCEL PROPOSAL
AND HAS
DETERMINED THAT IT IS NOT IN BEST INTERESTS OF NEWLINK'S
STOCKHOLDERS
* NEWLINK GENETICS CORP - REMAINS COMMITTED TO COMPLETING
ITS
PLANNED TRANSACTION WITH LUMOS, WHICH IS EXPECTED TO CLOSE IN Q1
OF CALENDAR YEAR 2020
Source text for Eikon: ID:nGNX5hbH45
Further company coverage: NLNK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)